Novartis 2023 Continuing Operations Results Investor Presentation

Novartis presents restated financial results from continuing operations for 2022 and H1 2023 following the shareholder-approved spin-off of Sandoz. The presentation separates consolidated income statements into continuing operations (Innovative Medicines division) and discontinued operations (Sandoz business) per IFRS requirements, showing net sales of $42.2B in FY2022 and $21.1B in H1 2023.